Azenta, Inc. $AZTA Holdings Raised by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. raised its stake in shares of Azenta, Inc. (NASDAQ:AZTA) by 88.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 109,344 shares of the company’s stock after buying an additional 51,226 shares during the period. John G Ullman & Associates Inc.’s holdings in Azenta were worth $2,310,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of AZTA. Allspring Global Investments Holdings LLC raised its holdings in shares of Azenta by 16.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 1,613,914 shares of the company’s stock worth $34,183,000 after acquiring an additional 225,867 shares in the last quarter. Illinois Municipal Retirement Fund boosted its position in Azenta by 13.6% during the first quarter. Illinois Municipal Retirement Fund now owns 24,649 shares of the company’s stock valued at $521,000 after purchasing an additional 2,943 shares during the last quarter. Calamos Wealth Management LLC purchased a new position in Azenta in the first quarter valued at about $283,000. Calamos Advisors LLC purchased a new position in Azenta in the first quarter valued at about $283,000. Finally, Principal Financial Group Inc. grew its stake in Azenta by 2.5% in the first quarter. Principal Financial Group Inc. now owns 199,252 shares of the company’s stock valued at $4,210,000 after purchasing an additional 4,810 shares in the last quarter. 99.08% of the stock is currently owned by hedge funds and other institutional investors.

Azenta Trading Down 1.8%

Azenta stock opened at $26.29 on Friday. The company has a market capitalization of $1.21 billion, a P/E ratio of -6.64 and a beta of 1.37. The firm’s fifty day simple moving average is $22.68 and its 200-day simple moving average is $26.35. Azenta, Inc. has a 1-year low of $15.93 and a 1-year high of $41.73.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.16). The business had revenue of $144.79 million during the quarter, compared to the consensus estimate of $148.47 million. Azenta had a positive return on equity of 1.23% and a negative net margin of 30.49%.The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.01 earnings per share.

Analyst Upgrades and Downgrades

AZTA has been the subject of a number of recent research reports. Weiss Ratings raised Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. Needham & Company LLC lowered their price target on Azenta from $44.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $39.50.

Azenta Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.